Recursion

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Variational AI is a company that uses generative AI to discover novel drug-like small molecules with optimized properties for defined targets. Their platform, Enki™, is the first commercially accessible foundation model for small molecules. It is designed to make generating novel molecule structures easy, with no data required. Users simply define their target product profile (TPP) and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results. The company was founded in September 2019 and is based in Vancouver, BC, Canada.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

Genesis Therapeutics is a cutting-edge platform that leverages molecular AI technology to discover and develop innovative medicines with exceptional potency and selectivity. The platform, known as GEMS (Generative AI for Drug Discovery), combines AI and physics research to identify drug candidates against challenging targets at an accelerated pace. The company's approach involves designing highly potent and selective drugs for chemically complex targets, driven by a team of collaborative minds across AI and biotech disciplines. Genesis Therapeutics is dedicated to advancing breakthrough medicines and bringing new hope to patients through its unique blend of technology and expertise.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

Exscientia is a technology-driven drug design and development company that combines precision design with integrated experimentation to create more effective medicines for patients faster. They operate at the interfaces of human ingenuity, artificial intelligence (AI), automation, and physical engineering, pioneering the use of AI in drug discovery. Exscientia aims to change the underlying economics of drug discovery by rapidly advancing the best scientific ideas into medicines for patients.

ESTsoft is a South Korean software company that develops and markets a wide range of software products and services, including operating systems, database management systems, and application software. The company was founded in 1995 and is headquartered in Seoul, South Korea. ESTsoft's mission is to "make the world more convenient and safer through AI." The company's products and services are used by a wide range of customers, including governments, businesses, and individuals. ESTsoft is a publicly traded company and is listed on the Korea Exchange. The company has a strong commitment to research and development and invests heavily in new technologies. ESTsoft has a number of partnerships with other companies, including Microsoft, IBM, and Oracle. The company is also a member of the World Economic Forum.

neurons.bio is an AI application that offers a unique collection of over 100 AI agents designed for drug development, medicine, and life science research. These agents perform specific tasks efficiently, retrieve data from various sources, and provide insights to accelerate research processes. The platform aims to revolutionize drug discovery and development by integrating cutting-edge LLM technology with domain-specific agents, reducing research costs and time to clinic.

Google DeepMind is a British artificial intelligence research laboratory owned by Google. The company was founded in 2010 by Demis Hassabis, Shane Legg, and Mustafa Suleyman. DeepMind's mission is to develop safe and beneficial artificial intelligence. The company's research focuses on a variety of topics, including machine learning, reinforcement learning, and computer vision. DeepMind has made significant contributions to the field of artificial intelligence, including the development of AlphaGo, the first computer program to defeat a professional human Go player.

The AI in Finance Summit is a leading conference that brings together experts in artificial intelligence and finance to discuss the latest trends and developments in the field. The summit features a variety of speakers, including researchers, practitioners, and investors, who share their insights on how AI is being used to transform the financial industry. The summit also provides a platform for attendees to network and learn from each other.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus's innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, a tool to identify and close gaps in care; LENS, a platform to find, access, and analyze multimodal real-world data; and ALGOS, algorithmic models connected to Tempus's assays to provide additional insight.

OpenCV.ai is a leading provider of computer vision software and services. The company's team of experts has extensive experience in developing optimized large-scale computer vision solutions. OpenCV.ai's expertise is helping businesses grow in a variety of industries, including medicine, manufacturing, and retail. The company's solutions are used by startups and Fortune 500 companies alike.

Veritone is a leading provider of artificial intelligence (AI) solutions for businesses. Its flagship product, aiWARE, is an enterprise AI platform that provides access to hundreds of cognitive engines through one common software infrastructure. Veritone's AI solutions are used by businesses in a variety of industries, including media and entertainment, recruitment, government, legal and compliance, and sports. Veritone's mission is to augment the human workforce by transforming use-case concepts into tangible, industry-leading applications and solutions.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Biofourmis is a healthcare technology company that provides a connected technology platform for care delivery and drug development. The platform enables healthcare systems and pharmaceutical companies to deliver care and conduct clinical trials remotely, and to collect and analyze data to improve patient outcomes. Biofourmis's solutions have been shown to improve clinical, operational, and economic outcomes, such as reducing 30-day readmissions by 70%, detecting deterioration 21 hours sooner, and reducing cost of care by up to 38%.

AiCure provides a patient-centric eClinical trial management platform that enhances drug development through improved medication adherence rates, more powerful analysis and prediction of treatment response using digital biomarkers, and reduced clinical tech burden. AiCure's solutions support traditional, decentralized, or hybrid trials and offer flexibility to meet the needs of various research designs.

IXICO is a precision analytics company specializing in intelligent insights in neuroscience. They offer a range of services for drug development analytics, imaging operations, and post-marketing consultancy. With a focus on technology and innovation, IXICO provides expertise in imaging biomarkers, radiological reads, volumetric MRI, PET & SPECT, and advanced MRI. Their TrialTracker platform and Assessa tool utilize innovation and AI for disease modeling and analysis. IXICO supports biopharmaceutical companies in CNS clinical research with cutting-edge neuroimaging techniques and AI technology.

Flora Incognita is an interactive plant species identification app that combines AI-supported plant identification with citizen science. Users can identify over 30,000 plant species, save observations, access extensive plant fact sheets, and contribute to scientific research. The app is free of charge, ad-free, and works offline, making it ideal for educational purposes and nature conservation initiatives.

System Pro is a cutting-edge platform that revolutionizes the way users search, synthesize, and contextualize scientific research, with a primary focus on health and life sciences. It offers a fast and reliable solution for accessing valuable information in the field of research. Users can create a free account to explore the platform's features and capabilities.

Synthace is a software and expertise platform designed for Discovery Biology Teams to streamline and optimize their experiments in assay development, media optimization, and purification process development. The platform offers software solutions, training, and on-site support from specialists to help scientists conduct experiments more efficiently and effectively. By leveraging multifactorial methods and automation, Synthace aims to accelerate drug discovery processes and deliver faster, definitive results.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

Deepcell is a company that develops technology for single-cell analysis. Their REM-I platform combines label-free imaging, deep learning, and gentle sorting to leverage single cell morphology as a high-dimensional quantitative readout. This allows researchers to gain insights into cells' phenotype and function to address important research questions across biology.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Wildlife Insights is an AI application that brings cutting-edge technology to wildlife conservation. It streamlines decision-making by providing machine learning models and tools to manage, analyze, and share camera trap data. Users can easily upload, identify, analyze, and discover wildlife through the platform, enabling better decisions to help wildlife thrive globally.

BioloGPT is an AI tool designed to answer biology-related questions with insights and graphs. It provides information on various topics such as maintaining a healthy gut microbiome, foods for a healthy immune system, effects of cannabis on the brain, risks of Covid-19 vaccines, and advancements in psoriasis treatment. The tool is updated daily and cites full papers to support its answers.

Bichos ID de Fucesa is an AI tool that allows users to explore and identify insects, arachnids, and other arthropods using artificial intelligence. Users can discover the most searched bugs, explore new discoveries made by the community, and view curated organisms. The platform aims to expand knowledge about the fascinating world of arthropods through AI-powered identification.

HoloEye.AI is a transformative AI biological intelligence company that leverages cutting-edge artificial intelligence technology to revolutionize the field of biological research. The platform offers advanced AI solutions for analyzing complex biological data, enabling researchers to gain deeper insights and accelerate scientific discoveries.

Lavo Life Sciences is an AI-accelerated crystal structure prediction application that aims to accelerate drug development by providing accurate crystal structure predictions for small molecule drugs. The application helps in de-risking pipelines, optimizing solid-state formulations, and avoiding late-stage surprises through cutting-edge AI technology. Lavo Life Sciences combines expertise in AI and computational chemistry to offer fast and efficient solutions for drug development teams, enabling them to discover novel polymorphs and make informed decisions to enhance drug development processes.

Cradle is a protein engineering platform that uses machine learning to design improved protein sequences. It allows users to import assay data, generate new sequences, test them in the lab, and import the results to improve the model. Cradle can be used to optimize multiple properties of a protein simultaneously, and it has been used by leading biotech teams to accelerate new and ongoing projects.

C&EN, a publication of the American Chemical Society, provides the latest news and insights on the chemical industry, including research, technology, business, and policy. It covers a wide range of topics, including analytical chemistry, biological chemistry, business, careers, education, energy, environment, food, materials, people, pharmaceuticals, physical chemistry, policy, research integrity, safety, and synthesis.

Cambrian Copilot is an AI tool designed for researchers and engineers to stay updated with the latest machine learning research. It provides access to over 240,000 ML papers, helps in understanding complex details, and automates literature reviews. The tool simplifies the process of discovering and accessing the most recent research developments in the field of machine learning.

NexusGPT is an AI tool that allows users to build and deploy custom AI agents for various workflows without the need for coding. It offers enterprise-grade AI solutions that can be integrated into any app, providing autonomous agents that can complete complex tasks, automate processes, and enhance productivity. With features like connecting to external plugins, enterprise-grade security, and deployment on existing apps, NexusGPT empowers users to create powerful AI agents effortlessly.

Emotion Logic Ltd is an AI tool that specializes in genuine emotion detection from voice data. The technology provides valuable insights across various sectors, including fraud investigations, healthcare, education, and customer service. Emotion Logic's advanced voice analysis capabilities help in deciphering unspoken emotions accurately, enhancing user experiences, and gaining valuable insights for decision-making processes.

functime is a time-series machine learning tool designed for scalability. It offers a comprehensive set of functions and features to facilitate time-series forecasting and analysis. With functime, users can easily install the tool, access documentation, tutorials, and API references. The tool provides scoring, ranking, and plotting functions for evaluating forecasts, making it a valuable resource for forecast analysts. Additionally, functime serves as an AI copilot, assisting users in analyzing trends, seasonality, and causal factors in their forecasts.

Kolank is an AI tool that offers a unified API with features such as load balancing, fallbacks, cost and performance metrics. Users can access models for generating text, images, and videos through simple API calls. The platform supports multiple programming languages like Python, JavaScript, and Curl, making it easy for developers to integrate AI capabilities into their applications.

Promptmakr is a platform that facilitates the buying and selling of AI prompts. It serves as a marketplace where users can find and purchase prompts for various AI applications. The platform aims to streamline the process of acquiring prompts, making it easier for developers and AI enthusiasts to access high-quality content to enhance their projects.

StockGPT is an AI-powered financial research assistant that provides knowledge of earnings releases, financial reports, and fundamental information for S&P 500 and Nasdaq companies. It offers features like AI search, customizable filters, up-to-date data, industry research, and more to help users analyze companies and markets efficiently.